| Bioactivity | Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727)[1]. Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3[2]. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice[3]. | ||||||||||||
| Invitro | Stattic (20 μM; 24 hours) inhibits STAT3 phosphorylation (Y705) and selectively inhibits P-STAT3 as demonstrated by the lack of inhibition of P-ERK1/2 in ALDH+ and D44+/CD24+ subpopulations of Panc-1 and HPAC pancreatic cancer cell lines[1]. Stattic (2.5, 5, 10 μM; for 4 h) significantly reduces the nuclear level of pSTAT3 and survivin in PC3M-1E8 cells at 10 μM. Stattic (2.5-10 μM; for 24 h) inhibits IL-6-induced STAT3 activation in a dose-dependent manner[2]. Stattic (2.5, 5, 10 μM; for 48 h) suppresses both the growth and induces apoptosis prostate cancer cells (PC3M-1E8 cells) with 10 μM. Stattic does not induce significant cell apoptosis with 2.5 μM, 5 μM[2]. Stattic (2.5, 5, 10 μM; for 48 h) shows significant S phase accumulation[2]. Stattic can not lead to significant morphological changes or apoptosis and has little STAT3 phosphorylation in A2780 cells and HUVECs[2]. | ||||||||||||
| Name | Stattic | ||||||||||||
| CAS | 19983-44-9 | ||||||||||||
| Formula | C8H5NO4S | ||||||||||||
| Molar Mass | 211.19 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|